Clinical trials
Hypertrophic Cardiomyopathy clinical trials
Below are recruiting hypertrophic cardiomyopathy clinical trials, each written for real people, not researchers. We’re tracking 78 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07077005Recruiting
Can Mavacamten Help You Exercise More?
This study looks at whether taking mavacamten for at least 12 weeks helps people with a certain type of heart disease (hypertrophic obstructive cardiomyopathy) exercise better. You'll have tests to check your heart's function and safety during exercise.
Munich, BavariaAges 18–99 - NCT06490250Recruiting
Breathing vs. movement exercises for hypertrophic cardiomyopathy
This study compares two types of gentle exercises—breathing muscle training and a traditional Chinese movement practice called Baduanjin—to see which helps people with hypertrophic cardiomyopathy feel better and improve their daily life. If you have a thickened heart muscle but are stable and have mild symptoms, you may be able to join.
IstanbulAges 18 years+ - NCT06368518Recruiting
Study of hypertrophic cardiomyopathy in Austria
This study tracks people with hypertrophic cardiomyopathy, a heart muscle disease, to learn more about the condition and improve care. It does not test a new treatment but collects health information over time.
Linz, LinzAges 18 years+ - NCT07382128Recruiting
Heart MRI to Understand Hypertrophic Cardiomyopathy
This trial uses a special heart MRI to better understand different types of hypertrophic cardiomyopathy (thick heart muscle). It may help doctors tell apart various forms of the condition and guide treatment.
Bologna, BOAges 18 years+ - NCT06610019Recruiting
Heart imaging study using MRI
This study uses heart MRI scans to learn more about cardiovascular health in adults. If you are 18 or older and have been referred for a heart MRI at Montefiore, you may be able to join.
The Bronx, New YorkAges 18 years+ - NCT02696135Recruiting
Study of Chinese people with hypertrophic cardiomyopathy
This study looks at people with hypertrophic cardiomyopathy (HCM), a heart condition that causes part of the heart muscle to thicken for no clear reason. It will compare how HCM is identified and studied, which may help doctors better understand and manage the condition in Chinese patients.
Beijing, Beijing MunicipalityAges Any age - NCT05610215Recruiting
Hybrid or catheter ablation for atrial fibrillation in hypertrophic heart
This trial compares two procedures to treat atrial fibrillation (an irregular heartbeat) in people who also have hypertrophic cardiomyopathy (thickened heart muscle). It looks at whether the hybrid approach or a catheter-based approach works better for controlling symptoms and heart rhythm.
BeijingAges 18 years+ - NCT05332691Recruiting
Beating-heart septal myectomy for thick-heart blockage
This trial studies surgery that removes part of the thick heart muscle while the heart is still beating to relieve a blockage that makes blood leaving the heart harder. It may help people with hypertrophic obstructive cardiomyopathy whose symptoms persist despite medication.
Wuhan, HubeiAges 8 years+ - NCT07361289Recruiting
Mavacamten for obstructive hypertrophic cardiomyopathy in China
This study looks at how well mavacamten works in real life for adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is thickened and blocks blood flow. It may help improve symptoms like shortness of breath or chest pain.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06381778Recruiting
Taiwan registry study on hypertrophic cardiomyopathy
This study creates a registry (a detailed record) for people with hypertrophic cardiomyopathy, a condition where the heart muscle is thicker than normal. It aims to learn more about the condition over time.
New Taipei CityAges 20 years+ - NCT07383025Recruiting
Mavacamten safety study for heart muscle disease in Japan
This study tracks the safety of Mavacamten in people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow). It helps doctors understand how the drug works in everyday use in Japan.
TokyoAges 18 years+ - NCT07372196Recruiting
Left bundle branch pacing after myectomy for hypertrophic cardiomyopathy
This trial is testing a new way to pace the heart (left bundle branch pacing) for people with hypertrophic cardiomyopathy who still have a dangerous heart rhythm problem after myectomy surgery. It aims to see if this pacing can reduce the risk of sudden cardiac death.
Novosibirsk, Novosibirsk OblastAges 18–75 - NCT05569382RecruitingPhase 4
Testing bisoprolol and verapamil in hypertrophic heart disease
This study tests whether two common heart medicines, bisoprolol and verapamil, improve symptoms in adults with non-obstructive hypertrophic cardiomyopathy. It may help you and your care team understand which medicine works better for symptom control and heart function.
Aarhus NAges 18 years+ - NCT07023614RecruitingPhase 2
Study of Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
This trial tests an investigational drug (ninerafaxstat) for people with a specific type of thickened heart muscle called non-obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve symptoms and exercise ability.
La Jolla, CaliforniaAges 18 years+ - NCT06775665Recruiting
Real-world study on hypertrophic cardiomyopathy in China
This study looks at how hypertrophic cardiomyopathy (HCM) affects people in China in real-world settings. It may help doctors understand the condition better and improve care for patients like you.
Hangzhou, ZhejiangAges 18 years+ - NCT07336290Enrolling by invitation
One-stop MRI for hypertrophic cardiomyopathy
This study uses a single, advanced heart MRI to get a complete picture of hypertrophic cardiomyopathy—a condition where the heart muscle is thickened. It aims to make diagnosis and treatment planning faster and easier for patients.
Ages Any age - NCT05489705Recruiting
Real-world registry for mavacamten and other obstructive HCM treatments
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
Anchorage, AlaskaAges 18 years+ - NCT06546137Recruiting
Registry for inherited heart conditions in Brazil
This study is building a national registry in Brazil to learn more about inherited heart conditions and improve care. If you have a family-related heart disease, you may be able to join and help advance cardiovascular healthcare.
Rio Branco, AcreAges Any age - NCT06813443Recruiting
Studying cardiomyopathy to find who needs a heart transplant
This study is looking at people with cardiomyopathy to understand which patients are most in need of a heart transplant. By joining, you will help doctors learn more about critical cases and improve care for heart muscle disease.
Bologna, Emilia-Romagna/BolognaAges 12 years+ - NCT04464655Recruiting
10-minute heart MRI protocol for people with heart conditions
This study uses a short, 10-minute heart MRI to check how well it works for people who need a clinically indicated heart scan. It may help streamline heart MRI testing, making exams faster while still providing useful heart information.
Montreal, QuebecAges 18 years+ - NCT07295613Enrolling by invitation
Registry of hypertrophic cardiomyopathy: regional features, genetics and course
This study is a registry that collects information about people with hypertrophic cardiomyopathy (a condition where the heart muscle is thickened) to better understand how it affects different people and to study its genetic causes. By joining, you help researchers learn more about this condition and how it progresses.
Moscow, Moscow RegAges Any age - NCT06730464Recruiting
Predicting dangerous heart rhythms in non-ischemic heart disease
This study uses heart MRI scans to predict who might develop dangerous heart rhythms. It's for people with certain types of non-ischemic heart disease who have already had an MRI with contrast.
Milan, ItalyAges 18 years+ - NCT07202897RecruitingPhase 3
Preventing blood clots in hypertrophic cardiomyopathy with rivaroxaban
This trial tests if the blood thinner rivaroxaban can prevent strokes in people with hypertrophic cardiomyopathy who have early signs of damage in their left atrium (the heart's upper chamber). You may qualify if you have this condition, are in a normal heart rhythm, and are between 40 and 80 years old.
AngersAges 40–80 - NCT02413450Enrolling by invitation
Using patient DNA cells to study inherited heart rhythm risks
This study uses your blood or genetic information to make “iPS cells,” lab-grown cells that can help researchers study inherited heart rhythm problems like LQTS, Brugada syndrome, CPVT, or early repolarization syndrome. It may help improve understanding of why these rhythms happen and guide future treatments.
Baltimore, MarylandAges 18–85
Hear when a new Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hypertrophic cardiomyopathy?
- Yes. Clin2 currently lists 78 recruiting hypertrophic cardiomyopathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hypertrophic cardiomyopathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hypertrophic cardiomyopathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.